Jefferies London 2026: Marea Therapeutics' CEO Josh Lehrer describes the ANGPTL4 target for targeting triglycerides (Marea is first in class) and compares and contrasts it to ANGPTL3 and APOE3
The company recently presented phase 2b data at AHA and published in NEJM. Dr. Lehrer also discusses the company's acromegaly program, and more.
Coverage brought to you by










.png)
